How a Drug Maker Profited by Slow-Walking a
Promising H.I.V. Therapy
https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html
Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.
https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html
Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.
Related:
Drugmakers Are ‘Throwing the Kitchen Sink’ to Halt
Medicare Price Negotiations
https://www.nytimes.com/2023/07/23/us/politics/medicare-drug-price-negotiations-lawsuits.html
The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law. Drugmakers are fighting the measure in court.
https://www.nytimes.com/2023/07/23/us/politics/medicare-drug-price-negotiations-lawsuits.html
The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law. Drugmakers are fighting the measure in court.